Harvoni is a drug combined with two others, such as Sofosbuvir and Ledipasvir. This medicine is used to treat the hepatitis C virus (HCV) in adults. Its presentation for sale is in tablets coated with a film; each tablet contains 90 mg of ledipasvir and 400 mg of sofosbuvir.
Harvoni is the first combination medicine used to treat serious infections with genotype 1 hepatitis C virus, which has been very effective, just once a day
Sofosbuvir is a nucleotide analog polymerase inhibitor. Ledipasvir is an inhibitor of the HCV NS5A replication complex. Both drugs combined in Harvoni intercept the enzymes that promote the spread of the hepatitis C virus.
The effectiveness of Harvoni was proven by clinical studies in patients who had not yet been treated and those who had not responded to previous treatments. The results were satisfactory, where almost 94% of those who received Harvoni achieved a positive virological response
However, this medicine is contraindicated for patients who suffer or have suffered from: liver problems other than hepatitis C, kidney problems, HIV, or heart problems. Similarly, it is not recommended for pregnant women.
How should Harvoni be taken?
It is usually taken once a day, with or without meals; what is recommended is that it be done at the same time. This medicine must be administered under medical supervision.
Some of the most common side effects when dealing with this drug are: feeling tired, fatigue, headache.
